EQT pursues Qiagen acquisition with €12B offer
by@Reuters
Summary
EQT has made a $12 billion bid to acquire Qiagen, a lab testing company, offering €46.50 per share—just an 8% premium over a rejected bid from Thermo Fisher six years ago. This acquisition follows a long history of unsuccessful takeover attempts, including a rejected €43 offer in 2020. Qiagen's recent struggles, including a decline in operating margins and modest sales growth projections, have made the deal appealing for EQT, which has significant experience in healthcare investments. However, the diagnostics sector is fraught with regulatory challenges and competitive pressures, which may hinder EQT's ability to improve Qiagen's financial performance post-acquisition.
Tokens
$QIA$EQT$TMO$BIOX
Analysis
EQT: EQT is a Swedish private equity firm with a substantial track record of investments in healthcare and life sciences companies. It is pursuing the acquisition of Qiagen to drive revenue growth and margin expansion in diagnostic testing areas such as tuberculosis and precision DNA/RNA analysis. Qiagen: Qiagen is a Dutch-German company focused on molecular diagnostics, laboratory testing solutions, and sample preparation technologies for research and clinical applications. The firm is at the center of a takeover by private equity firm EQT, which views its portfolio of testing capabilities as an opportunity for operational improvements outside public market pressures. bioMérieux: bioMérieux is a French company specializing in in vitro diagnostics and infectious disease testing solutions. It had explored a potential merger with Qiagen in earlier discussions that ultimately did not proceed. Thermo Fisher Scientific: Thermo Fisher Scientific is a US-based provider of life sciences tools, diagnostics, and laboratory equipment. It previously attempted to acquire Qiagen with a cash offer that shareholders rejected several years ago. Diagnostics Sector Challenges: Laboratory testing businesses face ongoing regulatory requirements and competitive pressures that complicate efforts to expand margins and revenue. Private Equity Healthcare Focus: EQT maintains significant exposure to healthcare and life sciences investments as part of its portfolio strategy.
Categories
macro